Cemiplimab

Evidence Level: L5

Predicted Indications: 5

Cemiplimab

Pharmacist Assessment Report

Cemiplimab: anti-PD-1 antibody → gallbladder adenosquamous carcinoma

One-Sentence Summary

Cemiplimab is an anti-PD-1 (programmed cell death 1) antibody that is marketed in Canada under the brand name LIBTAYO. The TxGNN model predicts it may be effective for gallbladder adenosquamous carcinoma, with a score of 0.9999. Currently there are 0 clinical trials and 0 publications that directly study this disease, so the support is model prediction only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	gallbladder adenosquamous carcinoma
TxGNN Prediction Score	0.9999
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Cemiplimab is a monoclonal antibody that binds human PD-1 (gene PDCD1) and blocks its interaction with PD-L1, with an IC50 below 1 nM in an ELISA. By releasing this checkpoint, it can restore T-cell activity against tumours. Detailed mechanism-of-action text is not available in the DrugBank data compiled for this report, but the pharmacology data confirm the PD-1 target.

The link to the predicted disease is mainly histological. Cemiplimab is established in cutaneous squamous cell carcinoma, and the predicted tumour has a squamous component, so PD-1 blockade could plausibly act on it. This reasoning is speculative. Adenosquamous biliary tumours are rare and have distinct biology, and no trial or publication in the data compiled for this report addresses this disease.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02487144	LIBTAYO	Not recorded	Not recorded

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-1 checkpoint inhibitor)
Myelosuppression Risk	Low; not a conventional cytotoxic agent. Please refer to the package insert warnings and precautions
Emetogenicity Classification	Low
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: Ten interaction records were compiled. Nine are Moderate-level interactions with corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone, methylprednisolone and deflazacort. The tenth is the pharmacological target record for PD-1 (CD279), which is not a drug interaction. Corticosteroids may blunt the immune activity that PD-1 blockade relies on, so their use should be reviewed case by case.

For warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high (0.9999), but no clinical trial or publication directly studies cemiplimab in gallbladder adenosquamous carcinoma. This disease is rare, and its biology differs from the cutaneous squamous cell carcinoma where cemiplimab works. The evidence level is therefore L5.

To proceed, the following is needed:

Clinical or real-world data on PD-1 blockade in adenosquamous biliary tumours (case series, registry data, PD-L1 and mutational-burden profiling)
Health Canada package insert warnings and contraindications, which are currently missing and block safety screening
Detailed mechanism-of-action data from DrugBank
A defined rationale for corticosteroid co-medication management
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.